MRTFA
Basic information
Region (hg38): 22:40410281-40636719
Previous symbols: [ "MKL1" ]
Links
Phenotypes
GenCC
Source:
- immunodeficiency 66 (Limited), mode of inheritance: Unknown
- immunodeficiency 66 (Limited), mode of inheritance: AR
Clinical Genomic Database
Source:
| Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
|---|---|---|---|---|---|
| Immunodeficiency 66 | AR | Allergy/Immunology/Infectious | An individual has been described with severe, early-onset, and recurrent infections, as well as reaction related to BCG vaccine, and and awareness and prompt and aggressive treatment of infections and related sequelae may be beneficial | Allergy/Immunology/Infectious | 26224645 |
ClinVar
This is a list of variants' phenotypes submitted to
- not_provided (734 variants)
- not_specified (187 variants)
- MRTFA-related_disorder (28 variants)
- Immunodeficiency_66 (11 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the MRTFA gene is commonly pathogenic or not. These statistics are base on transcript: NM_000020831.6. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 224 | 233 | ||||
| missense | 416 | 28 | 449 | |||
| nonsense | 4 | |||||
| start loss | 0 | |||||
| frameshift | 4 | |||||
| splice donor/acceptor (+/-2bp) | 0 | |||||
| Total | 1 | 0 | 426 | 252 | 11 |
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| MRTFA | protein_coding | protein_coding | ENST00000355630 | 12 | 226422 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 0.998 | 0.00232 | 125740 | 0 | 8 | 125748 | 0.0000318 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | 0.0178 | 528 | 529 | 0.998 | 0.0000313 | 5922 |
| Missense in Polyphen | 244 | 266.63 | 0.91512 | 3002 | ||
| Synonymous | -2.82 | 305 | 248 | 1.23 | 0.0000165 | 2014 |
| Loss of Function | 4.89 | 4 | 35.4 | 0.113 | 0.00000191 | 393 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.0000339 | 0.0000339 |
| Ashkenazi Jewish | 0.0000994 | 0.0000992 |
| East Asian | 0.00 | 0.00 |
| Finnish | 0.00 | 0.00 |
| European (Non-Finnish) | 0.0000445 | 0.0000439 |
| Middle Eastern | 0.00 | 0.00 |
| South Asian | 0.0000338 | 0.0000327 |
| Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Transcription coactivator that associates with the serum response factor (SRF) transcription factor to control expression of genes regulating the cytoskeleton during development, morphogenesis and cell migration. The SRF-MRTFA complex activity responds to Rho GTPase-induced changes in cellular globular actin (G-actin) concentration, thereby coupling cytoskeletal gene expression to cytoskeletal dynamics. MRTFA binds G-actin via its RPEL repeats, regulating activity of the MRTFA-SRF complex. Activity is also regulated by filamentous actin (F-actin) in the nucleus. {ECO:0000250|UniProtKB:Q8K4J6}.;
- Disease
- DISEASE: Note=A chromosomal aberration involving MRTFA may be a cause of acute megakaryoblastic leukemia. Translocation t(1;22)(p13;q13) with RBM15 (PubMed:11431691, PubMed:11344311). Although both reciprocal fusion transcripts are detected in acute megakaryoblastic leukemia (AMKL, FAB-M7), the RBM15-MRTFA chimeric protein has all the putative functional domains encoded by each gene and is the candidate oncogene (PubMed:11431691, PubMed:11344311). {ECO:0000269|PubMed:11344311, ECO:0000269|PubMed:11431691}.;
Recessive Scores
- pRec
- 0.122
Intolerance Scores
- loftool
- rvis_EVS
- -0.53
- rvis_percentile_EVS
- 20.91
Haploinsufficiency Scores
- pHI
- 0.204
- hipred
- Y
- hipred_score
- 0.722
- ghis
- 0.529
Essentials
- essential_gene_CRISPR
- essential_gene_CRISPR2
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- gene_indispensability_score
Mouse Genome Informatics
- Gene name
- Mrtfa
- Phenotype
- cellular phenotype; homeostasis/metabolism phenotype; muscle phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; endocrine/exocrine gland phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan);
Gene ontology
- Biological process
- positive regulation of transcription via serum response element binding;actin cytoskeleton organization;positive regulation of transcription by RNA polymerase II;smooth muscle cell differentiation
- Cellular component
- nucleus;nucleoplasm;cytoplasm;cytosol
- Molecular function
- transcription coactivator activity;actin binding;actin monomer binding;protein binding;leucine zipper domain binding